18 December 2025
18 December 2025
The new guidance marks a major policy shift to the vaccine framework that has been in place since 1991.
The EC approval follows the positive opinion issued by the European Medicines Agency’s CHMP in November 2025.
Construction at the Norton site is currently underway, with the new offerings anticipated to be operational by late 2027.
Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.
Harbour is eligible for payments of $90m, with potential development and commercial milestones of up to $1.035bn.
Targeted patient recruitment can increase the likelihood of trial success and help cultivate use of precision medicine.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
